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Simple Summary: Circulating tumour DNA (ctDNA) has been shown to be an informative biomarker
in melanoma. Here we analysed plasma ctDNA in a real-world metastatic melanoma cohort. We found
the kinetics of ctDNA decline are delayed in patients treated with immunotherapy compared to
those receiving MAPK inhibitors. Nonetheless, decreasing ctDNA levels within 12 weeks of
immunotherapy or BRAF/MEK inhibitors was strongly concordant with treatment response and
significantly associated with longer progression-free survival (PFS). Furthermore, exploratory analysis
of nine patients commencing anti-PD-1 therapy showed a trend of high tumour mutational burden
and neoepitope load in responders compared to non-responders. The results support the use of
ctDNA as a dynamic biomarker for assessment of response in melanoma patients.
Abstract: In this study, we evaluated the predictive value of circulating tumour DNA (ctDNA)
to inform therapeutic outcomes in metastatic melanoma patients receiving systemic therapies.
We analysed 142 plasma samples from metastatic melanoma patients prior to commencement
of systemic therapy: 70 were treated with BRAF/MEK inhibitors and 72 with immunotherapies.
Patient-specific droplet digital polymerase chain reaction assays were designed for ctDNA detection.
Plasma ctDNA was detected in 56% of patients prior to first-line anti-PD1 and/or anti-CTLA-4
treatment. The detection rate in the immunotherapy cohort was comparably lower than those with
BRAF inhibitors (76%, p = 0.0149). Decreasing ctDNA levels within 12 weeks of treatment was
strongly concordant with treatment response (Cohen’s k = 0.798, p < 0.001) and predictive of longer
progression free survival. Notably, a slower kinetic of ctDNA decline was observed in patients treated
with immunotherapy compared to those on BRAF/MEK inhibitors. Whole exome sequencing of
ctDNA was also conducted in 9 patients commencing anti-PD-1 therapy to derive tumour mutational
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burden (TMB) and neoepitope load measurements. The results showed a trend of high TMB and
neoepitope load in responders compared to non-responders. Overall, our data suggest that changes
in ctDNA can serve as an early indicator of outcomes in metastatic melanoma patients treated with
systemic therapies and therefore may serve as a tool to guide treatment decisions.
Keywords: circulating tumour DNA (ctDNA); melanoma; BRAF; response; targeted therapy;
immunotherapy; neoantigen load; tumour mutational burden

1. Introduction
In recent years, improved knowledge of melanoma pathogenesis has led to the development of
BRAF and MEK inhibitors that target tumours carrying BRAF oncogenic mutations, accounting for
40–50% of all melanoma cases. Similarly, antibody-mediated blockade of immune checkpoints,
particularly the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and the programmed
cell-death protein 1 (PD-1), have markedly improved patient outcome in the last 5 years [1–6].
However, a significant number of patients do not achieve sustained benefit from either targeted therapy
or immunotherapy [2–6]. The most appropriate treatment sequence or therapy combinations that can
maximise patient outcomes remains controversial [7,8]. Predictive biomarkers of therapy response that
can be assessed prior to initiation of treatment and early during therapy are critical to guide clinical
management of metastatic melanoma.
Analysis of tumour specific cell-free DNA (cfDNA) has been previously reported to be a reliable
companion diagnostic biomarker in oncology [9–12]. In melanoma, ddP (ctDNA) is a potential
non-invasive alternative to tumour tissue biopsy for molecular profiling and longitudinal disease
monitoring in the metastatic setting [13–23]. In addition, baseline ctDNA levels and subsequent
decline with treatment have been indicated as an early predictor of tumour response and clinical
benefit [13,15,24,25]. To confirm the utility of ctDNA as a clinical biomarker, its ability to monitor
and/or predict treatment response and clinical outcome requires further validation in a large cohort of
melanoma patients, especially in those treated with immunotherapy.
In melanoma, BRAF mutant ctDNA has been found to be a robust biomarker for disease burden and
tumour status of patients prior to and during targeted treatment [13,20–22]. However, many patients
receiving immunotherapy, are BRAF wild-type (WT). Thus, the detection rate of ctDNA and the value of
ctDNA-based longitudinal monitoring in non-BRAF melanoma patients need to be specifically assessed.
Mutations, genetic rearrangements, insertions and deletions can encode novel, cancer-specific
neoantigens. Activation of T-cells is initiated by the recognition of novel peptides presented by
human leukocyte antigens (HLA) complex. A high tumour mutational burden (TMB) was associated
with better survival outcomes in non-small cell lung cancer (NSCLC) [26–30], melanoma [31,32]
and other cancers. Nonetheless, the predictive value of tissue-derived TMB for immunotherapy
response needs further scrutiny and standardisation [33–35]. In this context, ctDNA has the potential to
comprehensively capture the mutational profile of all existing metastases [20]. However, whether this
biomarker presents as an easily accessible and suitable tumour source for whole exome mutational load
analysis and TMB measurement or neoepitope predictions in melanoma needs to be further defined.
In this study, we aimed to ascertain the clinical utility of ctDNA to inform treatment response and
survival in metastatic melanoma patients receiving systemic therapy. We compared ctDNA levels,
detection rates, decay kinetics and predictive value between patients treated with immune checkpoint
inhibitors and targeted therapies. We also explored whether ctDNA can be used for estimating tumour
mutational and neoepitope load, to predict response to immune checkpoint inhibiting therapies.
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2. Results
2.1. Plasma ctDNA Detection in Melanoma Patients Commencing Systemic Therapy
We first evaluated the rate of ctDNA detection in 142 plasma samples collected prior to treatment
initiation (Figure 1). From these 142 samples, 72 were treated with immunotherapy and 70 with targeted
therapy. Both cohorts were mainly formed by middle age patients (50–69 years of age), males and
with widespread disease (M1c). In the immunotherapy cohort, 30 patients were BRAF mutant (42%),
20 were NRAS mutant (28%) and 22 patients had other driver mutations that were used to track the
tumour (Table S2). In this cohort, the 41 patients were treated with anti-PD1 inhibitors, 12 patients
were treated with anti-CTLA-4 inhibitors and 19 patients with a combination of both (26%). On the
other hand, most patients in the targeted therapy cohort were treated with combination of BRAF/MEK
inhibitors, while only 5 patients were treated with single targeted therapy agent. The ctDNA detection
rate was 65% overall but patients with one or more prominent visceral metastases (M1c), particularly in
the liver, bone and lung, had significantly higher ctDNA detection rates when compared to those with
M1a disease (p = 0.0015; Figure 1A).
Similarly, median ctDNA levels were significantly higher in M1c patients compared with M1a
(p = 0.001) or M1b (p = 0.015). In addition, ctDNA levels in patients with M1d and extracranial disease
were significantly higher compared with M1a disease (p = 0.047). Notably, none of the ten M1d
patients with brain only metastases had detectable ctDNA (Figure 1A), indicating that ctDNA levels
are influenced by the site of metastases.
2.2. Baseline ctDNA Detection Prior Systemic Treatments
We then compared the ctDNA detection rates in plasma collected prior to commencing treatment
with immune checkpoint inhibitors or targeted agents. We observed reduced ctDNA concentrations
and a significantly lower detection rate in patients receiving immunotherapy when compared to those
receiving BRAFi ± MEKi (56% vs. 76%; p = 0.009; Figure 1B).
Due to the difference in ctDNA detection rates between the targeted therapy and immunotherapy
groups, we evaluated whether the mutational target used for ctDNA analysis influenced these results.
Comparison of the detection rate of ctDNA between mutational targets demonstrated no significant
difference between ctDNA levels and detection rate (geometric mean: 19.2 copies/mL, 67/100, 67%)
in patients with BRAF versus patients with other melanoma-associated mutations (geometric mean:
13.7 copies/mL, 26/42, 62%; Figure 1C).
To determine if ctDNA levels are influenced by the line of therapy, we compared ctDNA levels in
21 BRAF mutant patients that received first-line targeted therapy and second-line immunotherapy
(Figure 1D). This sequence of treatment is commonly used for BRAF mutant melanoma in Australia.
Despite not showing statistical significance, ctDNA detection rate was lower in patients commencing
second-line treatment (81% vs. 48%, p = 0.100). This result is likely influenced by the effectiveness of
regular radiological monitoring in identifying disease progression at low tumour burden.
2.3. Longitudinal ctDNA Monitoring for Prediction of Response
We further investigated whether ctDNA positivity at baseline and early during the treatment
course were correlated with treatment response. A total of 84 patients with longitudinal blood
collections within 12 weeks of treatment were included and stratified according to treatment, that is,
targeted therapy (N = 47) vs. immunotherapy (N = 37) and divided into three groups depending
on the ctDNA profile during the first 12 weeks of treatment (Figure 2A). Similar to that shown by
Lee et al. [24] Group A consisted of patients with undetectable ctDNA levels at baseline and during
12 weeks of therapy or non-significant ctDNA changes. Group B had detectable baseline ctDNA that
became undetectable or significantly reduced during treatment and group C includes patients that
were either ctDNA positive or negative at baseline with static or significantly increased levels during
the first 12 weeks of therapy. Overall, groups A and B represented patients that showed a biological
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By contrast, two patients (538 and 493) were found to have a clinical response to pembrolizumab and
dabrafenib/trametinib, respectively but no biological response was observed.

Figure 2. ctDNA levels early during treatment relative to clinical response. (A) Columns represent
each patient, best clinical response, treatment type and longitudinal quantitative ctDNA results.
Patients treated with immunotherapy or targeted therapy were stratified into three profile groups:
A = undetectable ctDNA at baseline and during treatment with a biological response, B = detectable
ctDNA at baseline that became undetectable during treatment or had a significant biological response
and C = detectable/undetectable ctDNA at baseline that remained or became detectable during therapy
without significant biological response. * Significant Biological Response. b Presence of only intracranial
malignant disease at baseline or at PD. (B) Concordance between best clinical response at 6 months
and biological ctDNA response within the 12 weeks of treatment. Patients categorised as clinically
responders (PR/CR, N = 61), patients with stable disease (SD, N = 7) and patients with disease
progression (PD, N = 16) and, ctDNA responders (Group A and B; N = 69) or non-responders (Group C;
N = 15) based on their biological ctDNA response over the first 12 weeks of treatment. Abbreviations:
ND = Not detectable; NSD = Non-significant decrease. (C) Plasma ctDNA levels at baseline and
follow-up in patients that responded to targeted therapy (N = 26) and to immunotherapy (N = 6).
P-values of paired t-tests are indicated. The geometric mean ctDNA concentration is indicated for each
group by a dashed red line.

We next compared the biological ctDNA response with longitudinal blood collection for a period
of 24 weeks after starting treatment. In this cohort, most patients treated with anti-CTLA-4 and
anti-CTLA-4/PD-1 did not show radiological response to therapy and their ctDNA levels remained
high (Figure S2A,B). By contrast, 17 of the 21 (81%) patients receiving anti-PD-1 immunotherapy had a
partial response (PR) or complete response (CR) (Figure S2C). The clinical response rate in the targeted
therapy cohort was also high (41/47, 87%) but a number of these patients (10/41, 24%) developed
resistance and relapsed within the first 24 weeks of therapy, with 9 of them demonstrating rebounding
ctDNA levels (Figure S2D).
We analysed patients with objective clinical response that had detectable ctDNA at baseline and
assessable follow-up samples. Within these groups, ctDNA dropped significantly by 3-6 weeks in the
targeted therapy cohort (N = 26, p < 0.0001; Figure 2C). In contrast, most patients (67%) who responded
to immunotherapy had detectable ctDNA levels at first follow-up and, only had the significant drop to
undetectable levels on their second follow-up by 12-18 weeks (p = 0.004, Figure 2C).
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2.4. Longitudinal ctDNA Monitoring for Prediction of Survival
We evaluated whether the ctDNA changes during the first 12 weeks of treatment (groups A, B or C)
had prognostic value in patients treated with immunotherapy. For the survival analysis, patients
receiving single-agent immunotherapy ipilimumab (N = 8) were excluded due to their poor response
rate and rapid transition into anti-PD-1, which may confound survival analysis. Clinical characteristics
across the three groups were similar for age, sex, tumour stage, the prevalence of brain metastases and
prior lines of treatment (Table S3).
In patients receiving immunotherapy, groups A and B had significantly longer progression free
Cancers 2020, 12, x
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Figure 3. ctDNA levels early during treatment relative to survival. Progression free survival (PFS)
(C,D) stratified into the three previously detailed profile groups A, B and C. Cox regression p-values,
and overall survival (OS) curves for patients treated with (A,B) immunotherapy or targeted therapy
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group B is an independent predictor of decreased PFS (HR = 3.45, 95% CI = 1.02 to 11.65, p = 0.046)
but not of OS (p > 0.05; Table S4). The presence of brain metastases only and an Eastern Cooperative
Oncology Group (ECOG) performance status above 3 were also predictors of shorter PFS and OS.
Due to the low number of samples in group C (N = 3), these patients were excluded from the analysis.
2.5. Measuring Mutational Burden Using ctDNA
Plasma ctDNA analysis constitutes an attractive approach for real-time assessment of tumour
mutational profile and alleviates caveats associated with tissue biopsies including tumour heterogeneity.
Here, we determined the feasibility of quantifying mutational load in patient-derived cfDNA.
We screened melanoma patients treated with the anti-PD-1 inhibitor as a first- or second-line treatment,
with a ctDNA fraction of more than 7% abundance by ddPCR. Nine patients were selected and
dichotomised according to their best clinical response to therapy, with responders noted as having
either a PR, CR or prolonged stable disease (SD). Non-responders are those without clinical or
objective response and who had progressive disease (PD) within 6 months of treatment initiation.
Clinical characteristics for these patients are described in Table S5.
Mutational data were obtained from the nine patients, with the number of mutations ranging from
1–58 per Mb of DNA (Table 1). While patients that responded to anti-PD-1 inhibitor had higher TMB
compared to non-responders (mean: 21 vs. 6 per Mb), the difference was not statistically significant
(Figure 4A). Nonetheless, our results may be confounded by the small sample size analysed for TMB.
Table 1. Mutational burden and predicted neoepitope load of nine melanoma patients.
Response

Sample ID

Mutational Burden
(per Mb)

Predicted Neoantigens
IC50 < 500 nM

Predicted Neoantigens
IC50 < 50 nM

Responders
(R)

MP0104
MP0105
MP0201
MP0302
MP0303

22
2
4
58
22

1362
131
432
1516
429

236
32
86
259
57

Non-Responders
(NR)

MP0102
MP0103
MP0301
MP0304

10
1
1
14

439
114
25
469

105
25
3
75

As mutational burden alone did not explain clinical benefit from anti-PD-1 inhibitors,
we hypothesised that the presence of specific tumour neoantigens might explain the varied
dichotomised patients that are likely to benefit from this immunotherapy. To identify these neoepitopes,
the HLA-I phenotype of each patient were identified and the bioinformatics pipeline for pVACSeq
(https://github.com/griffithlab/pVAC-Seq) was used for neoepitope prediction.
The number of predicted neoepitopes with a binding affinity of IC50 < 500 nM ranged from 25–1516
and was higher in responders (mean = 774) versus non-responders (mean = 262) to immunotherapy
(Figure 4B). The number of predicted neoepitopes with a strong binding affinity (IC50 < 50nM) ranged
from 3–259 and was similarly higher in responders compared to non-responders (mean = 134 vs. 52,
Figure 4C). However, the difference in the number of neoepitopes in these two groups was again not
significant (p > 0.05). Nonetheless, the number of neoepitopes correlated with the mutational burden
(Figure 4D,E). Overall, there was a trend that high neoepitope load was associated with response to
anti-PD-1 treatments. Nevertheless, three of the five responders had neoepitope loads in the same
range as the non-responders, indicating that at a singular patient level, this parameter alone cannot be
used for treatment decisions.
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reflects the time interval necessary to unleash an immune response to cancer [38], which needs to be
taken as an important consideration when monitoring response to different types of treatment through a
liquid biopsy. The current treatment approach for melanoma is based on evaluating disease progression,
followed by treatment modification to potentially improve patient outcomes and discontinue ineffective
therapy. Our data suggest that an observation period may be required prior to conclusive evaluation
of therapeutic benefits to immunotherapy and treatment modification decisions.
While ctDNA was found to be a reliable prognostic and surveillance biomarker, it is not without
limitations. A significant roadblock for ctDNA analysis in this study was the low detection rate of
ctDNA prior to anti-PD-1 and/or anti-CTLA-4 treatment compared with targeted therapy. As indicated
above, most patients with detectable ctDNA have prominent visceral metastases, particularly to the
liver. The variation of tumour cell turnover at different metastatic sites may have an impact on the
detectability of ctDNA. In addition, the low detection rate may have been affected by the specificity of
the assay used for ctDNA analysis. Aside from our in-house BRAF assays, which have been previously
reported to have high specificity and sensitivity [39], assays for other mutations have a lower limit of
detection due to noise [21]. Differences in assay threshold may also affect the detection rate of ctDNA
in melanoma patients treated with immune-checkpoint inhibitors. Thus, the site of metastases and the
assay specificity of the mutational target for ctDNA analysis appears to highly influence the variation
in the detection rate observed in this study.
Previous studies have demonstrated the predictive value of tissue-derived mutational and
neoepitope load for immunotherapy response in NSCLC [26,27] and melanoma [31]. In this study,
we also explored the potential utility of ctDNA for mutational and neoepitope load analysis in melanoma.
Gandara et al. [30] demonstrated the utility of blood tumour mutational burden as a clinically-actionable
biomarker for anti-PD-L1 in NSCLC. Similarly, our exploratory analysis also demonstrated that whole
exome sequence (WES)-defined molecular analysis for clarifying tumour mutational burden in ctDNA
is possible. In our cohort, mutational load was unable to discriminate between responders and
non-responders to anti-PD-1 inhibitor. Nonetheless, we observed a trend showing high neoepitope
load in patients that achieved clinical benefit to anti-PD-1 blockade. The small sample size was not
sufficient to discriminate between responders and non-responders to immunotherapy. These findings
may be confounded by the small sample size mostly consisting of patients with high levels of ctDNA
(>7% frequency abundance). WES analysis imposed the need to select for patients with high ctDNA
fraction, which excluded most samples in our cohort. On the other hand, mutational burden derived
from targeted sequencing has been previously shown to be sufficient for stratifying responders and
non-responders to immunotherapy [30]. Thus, a targeted approach, with the addition of unique
molecular identifiers (UMI), may be more fitting for ctDNA mutational burden analysis, as it will be
able to control for PCR errors and allow interrogation of variants at low allelic fraction (<1%).
4. Materials and Methods
4.1. Patients
We analysed a total of 142 plasma samples collected prior to commencing systemic therapy and
227 follow-up samples collected within 24 weeks of treatment initiation from 118 metastatic melanoma
patients enrolled in the study between 2013–2018 at Sir Charles Gairdner Hospital (SCGH) and Fiona
Stanley Hospital (FSH) in Perth, Western Australia. A subset of 24 patients were considered as baseline
for their first- and second-line therapy. Additional details of study design and patient inclusion or
exclusion criteria in the different analyses can be found in Figure S1. The study was conducted in
accordance with the Declaration of Helsinki and the protocol was approved by the Human Research
Ethics Committee from Edith Cowan University (No. 11543 and No. 18957) and Sir Charles Gairdner
Hospital (No. 2013-246). Written consent was obtained from all patients under approved human
research ethics committee which complied with the Declaration of Helsinki. Patients were clinically
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monitored with median follow-up duration of 113 weeks (range: 28–286 weeks). Patient characteristics
and clinical parameters are summarised in Table S1.
4.2. Treatment Response and Disease Progression Assessment
Tumour disease responses were assessed radiologically by computed tomography (CT) and/or
fluorodeoxyglucose positron emission tomography (FDG-PET) scans at two to three
monthly intervals. Patients were defined as responders if they had significant reduction in tumour
size by the RECIST 1.1 on CT or FDG-PET scan as per the treating clinician or presented a durable
stable disease lasting more than 6 months. PFS was defined as the time interval between the start
of therapy and the date of first clinical progression. OS was defined as the time interval between
the start of therapy and death. Additionally, metastatic melanoma patients were stratified into four
M-subcategories at baseline based on the location of the metastases [40].

18 F-labeled

4.3. Statistics
Differences between ctDNA levels were estimated by unpaired t-test from the log transformed data.
Paired t-test was used to evaluate the difference between ctDNA levels at first and second-line treatment
in BRAF mutant patients. Differences between the detection rates were assessed using one-sided
Fisher’s exact test. PFS and OS were estimated using the Kaplan-Meier method and differences
were evaluated using Mantel-Cox tests. Concordance between the clinical response and the ctDNA
kinetics was calculated using Fisher’s exact test and the Cohen kappa measure with 95% CI from
1000 bias-adjusted and accelerated bootstrap (BCa) replications. Statistical difference between baseline
and follow-up ctDNA levels from the same individuals were assessed by the Poisson test, using the
minimum and maximum values plus total droplet counts as analytical variables [41]. Frequencies and
percentages by each group along with their corresponding P-values of two-sided chi-squared or the
Fisher’s exact test are reported in Table S3. All covariates were entered into a Cox proportional hazard
model for multivariable analysis. The final model was chosen using a backward conditional selection
procedure for selection of predictors of PFS and OS as reported in Table S4. The unpaired two-tailed
t-test was used to compare mutational and neoepitope load between patients that were responders
or non-responders to anti-PD-1 immunotherapy. Pearson correlation was used to determine the
correlation between mutational burden and neoepitope load. All statistical analyses were performed
using R version 5.2 (https://www.r-project.org/), GraphPad Prism version 5 (GraphPad Software, Inc.,
San Diego, CA, USA) and SPSSv22.0 (IBM, Armonk, NY, USA). Results were considered statistically
significant at p < 0.05.
5. Conclusions
In conclusion, ctDNA has significant clinical value as a biomarker of prognosis and therapeutic
response for melanoma. Nonetheless, limitations inherent to ctDNA analysis need to be clearly defined
and thoroughly addressed prior to its implementation in the clinic.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/12/3793/s1,
Additional Material and Methods. Figure S1: Flow chart showing group of samples included in the analyses,
Figure S2: Kinetics of ctDNA decay, Table S1: Demographic, clinicopathologic and treatment characteristics
of included samples, Table S2: Specificity of ddPCR assays, Table S3: Clinical characteristics at baseline of
the melanoma patients categorised in Groups A, B and C included in the survival analysis (N = 76), Table S4:
Univariable and multivariable Cox proportional-hazards regression analysis for associations between ctDNA
levels and survival, Table S5: Clinical characteristics of melanoma patients in this pilot cohort.
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